Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-Mouse PD-1 & CD47 Bispecific Antibody (Iv0241)

Catalog #:   VMG17603 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: FuncS
Accession: Q02242 & Q61735
Overview

Catalog No.

VMG17603

Species reactivity

Mouse

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Target

Bispecific, Programmed cell death protein 1, Protein PD-1, mPD-1, CD279, Pdcd1, Pd1, Leukocyte surface antigen CD47, Integrin-associated protein, IAP, CD47, Cd47

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q02242 & Q61735

Applications

FuncS

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0241

Data Image
References

Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade., PMID:40537244

Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609

Upregulation of PD-1 on Peripheral T cells Subsets is Associated with Parkinson's Disease., PMID:40536591

Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells., PMID:40536473

H3K36me3-Guided m6A Modification of Oncogenic L1CAM-AS1 Drives Macrophage Polarization and Immunotherapy Resistance in Hepatocellular Carcinoma., PMID:40536332

Palmitoylation-driven immune dysregulation and prognostic signature in low-grade glioma: a multi-omics and functional validation study., PMID:40535771

Case Report: Cytoreductive nephrectomy and thrombectomy in metastatic renal cell carcinoma with venous tumor thrombus: a case using indocyanine green fluorescence-guided laparoscopy., PMID:40535141

Combination of immune checkpoint inhibitors with multi-targeted tyrosine kinase inhibitors for second- or later-line therapy of non-small cell lung cancer: a systematic review and meta-analysis., PMID:40535065

Colonizable probiotic Lactobacillus paracasei R3 enhances ICI therapy via modulating PBMCs differentiation., PMID:40535013

F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies., PMID:40534867

Role of CD28+ PD-1+ Tc cells in immune response and prognosis prediction in hepatocellular carcinoma., PMID:40534863

Janus kinase and signal transducer and activator of transcription inhibitors in type 1 diabetes and immune checkpoint-related diabetes: current status and future perspectives., PMID:40534861

Treatment strategies for rapid recurrence and progression after surgery for stage I pulmonary pleomorphic carcinoma: a case report and literature review., PMID:40534846

Tissue-Resident Memory and Follicular/Peripheral Helper PD-1+ T Cells Infiltrate Lesional Skin in Atopic Dermatitis., PMID:40534582

Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response., PMID:40534172

The PD-1/PD-L1 pathway and Epstein-Barr virus., PMID:40533842

Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort., PMID:40533655

Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis., PMID:40532761

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664

An evaluation of Nivolumab and ipilimumab for the treatment of resectable stage III melanoma., PMID:40531544

Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma., PMID:40531258

Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma., PMID:40531216

PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-Mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis., PMID:40531080

Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers., PMID:40530506

Therapeutic potential of adenosine receptor modulators in cancer treatment., PMID:40530308

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition., PMID:40530179

Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors., PMID:40529897

First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study., PMID:40529764

Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study., PMID:40529756

Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study., PMID:40529754

Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation., PMID:40529668

The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study., PMID:40529375

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging., PMID:40529364

The next generation of immunotherapies for lung cancers., PMID:40528044

HAPIR: a refined Hallmark gene set-based machine learning approach for predicting immunotherapy response in cancer patients., PMID:40527973

Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer., PMID:40527175

Tumour and adipose tissue uptake on 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) predict immunotherapy response in recurrent or metastatic nasopharyngeal carcinoma., PMID:40527159

Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial., PMID:40526879

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia., PMID:40526840

Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma., PMID:40522918

The Ave-Rec trial: Phase II trial of PDL1/PD-1 blockade with Avelumab post Chemoradiotherapy for locally advanced resectable T3B-4/N1-2 Rectal cancer., PMID:40522298

Acupuncture Potentiates anti-PD-1 Efficacy by Promoting CD5+ Dendritic Cells and T Cell-Mediated Tumor Immunity in a Mouse Model of Breast Cancer., PMID:40521704

A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers., PMID:40521348

Boosting mRNA cancer vaccine efficacy via targeting Irg1 on macrophages in lymph nodes., PMID:40521193

Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study., PMID:40521168

Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study., PMID:40521010

Efficacy and toxicity of PD-1 inhibitor combined with induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancers., PMID:40520879

Gut microbiota is associated with the disease characteristics of patients with newly diagnosed diffuse large B-cell lymphoma., PMID:40520871

Bibliometric analysis of global research on PD-L1/PD-1 pathway and neurodegenerative diseases over the last two decades (2004-2023)., PMID:40520531

High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitors., PMID:40520330

Datasheet
$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-Mouse PD-1 & CD47 Bispecific Antibody (Iv0241) [VMG17603]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only